Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727, Paclitaxel, and Pembrolizumab in Metastatic Triple-Negative Breast Cancer
NCT05673200Phase 1Suspended
- Sponsor
- National Cancer Institute
- Start
- Sep 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inqovi in triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Primary endpoints: Maximally Tolerated Dose at 28 days and Safety Profile up to 4 years. Started Sep 2023; status: suspended.
02
Drugs
inqovi
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05673200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673200.